US 12,285,251 B2
Systems, devices, and methods related to the individualized calibration and/or manufacturing of medical devices
Steven Scott, Pleasanton, CA (US); Christopher J. Bennell, Carterton (GB); Claire Bhogal, Witney (GB); Katie A. Cranfield, Reading (GB); Marc B. Taub, Oxford (GB); Bree M. Winter, Witney (GB); Owen D. Reynolds, Cricklade (GB); Jean-Pierre Babka, Alameda, CA (US); Dharmendra S. Patel, Stanton Harcourt (GB); Christopher A. Thomas, Cheltenham (GB); Udo Hoss, Castro Valley, CA (US); Mark S. Yahnke, Alameda, CA (US); and Tahir S. Khan, Fremont, CA (US)
Assigned to ABBOTT DIABETES CARE INC., Alameda, CA (US)
Filed by ABBOTT DIABETES CARE INC., Alameda, CA (US)
Filed on Dec. 6, 2021, as Appl. No. 17/543,633.
Application 17/543,633 is a continuation of application No. 17/306,833, filed on May 3, 2021, granted, now 11,191,463.
Application 17/306,833 is a continuation of application No. 15/999,212, filed on Aug. 17, 2018, granted, now 10,993,646, issued on May 4, 2021.
Claims priority of provisional application 62/547,635, filed on Aug. 18, 2017.
Prior Publication US 2022/0087576 A1, Mar. 24, 2022
Int. Cl. A61B 5/1495 (2006.01); A61B 5/00 (2006.01); A61B 5/145 (2006.01); A61M 1/16 (2006.01)
CPC A61B 5/1495 (2013.01) [A61B 5/14503 (2013.01); A61B 5/14532 (2013.01); A61B 5/14546 (2013.01); A61B 5/0002 (2013.01); A61B 2560/0223 (2013.01); A61B 2562/12 (2013.01); A61M 1/1603 (2014.02)] 31 Claims
OG exemplary drawing
 
1. A continuous glucose monitoring system, comprising:
an in vivo sensor configured to generate a signal associated with a glucose level, wherein a first portion of the in vivo sensor is configured to be positioned beneath a skin surface of a user in the subcutaneous space and a second portion of the in vivo sensor is configured to remain outside the user; and
an on-skin sensor control unit, wherein the in vivo sensor is coupled to the sensor control unit and wherein the sensor control unit is programmed to process the generated signal from the in vivo sensor to generate a processed result that is representative of a glucose level of the user using calibration information, wherein the calibration information comprises a sensing characteristic of the in vivo sensor, and wherein the sensing characteristic is determined based at least in part on f1(RMPA) and f2(RMPB);
wherein f1 is a first nonlinear function of RMPA, and f2 is a second nonlinear function of RMPB; and
wherein RMPA is a first manufacturing parameter, and RMPB is a second manufacturing parameter.